Exposed: 10 CENT Crypto to Explode April 20th?

The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…

Edwin Kania, Jr. Biography and Net Worth

Director of TransMedics Group

Edwin M. Kania Jr. serves as Independent Director of the Company. Mr. Kania is the managing partner and chairman of FarField Partners, a personal venture capital investment and advisory firm. Mr. Kania was co-founder of Flagship Ventures and served as Flagship’s Chairman between 2001 and 2014. He continues as Managing Partner for the three Flagship funds raised during that period and also continues as Managing Partner for the predecessor OneLiberty Funds that were an early lead investor in our company. During Mr. Kania’s 35 years in the venture capital industry, he has served on the boards of numerous privately and publicly held companies, including previous board positions at Acceleron Pharma and Selecta Biosciences. Mr. Kania earned his Bachelor’s degree in physics from Dartmouth College and his MBA from Harvard Business School.

What is Edwin M. Kania, Jr.'s net worth?: The estimated net worth of Edwin M. Kania, Jr. is at least $12.63 million as of January 14th, 2020. Mr. Kania, Jr. owns 141,472 shares of TransMedics Group stock worth more than $12,626,376 as of April 26th. This net worth approximation does not reflect any other assets that Mr. Kania, Jr. may own. Learn More about Edwin M. Kania, Jr.'s net worth.
How do I contact Edwin M. Kania, Jr.?: The corporate mailing address for Mr. Kania, Jr. and other TransMedics Group executives is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. TransMedics Group can also be reached via phone at (978) 552-0900 and via email at [email protected]. Learn More on Edwin M. Kania, Jr.'s contact information.
Has Edwin M. Kania, Jr. been buying or selling shares of TransMedics Group?: Edwin M. Kania, Jr. has not been actively trading shares of TransMedics Group during the last quarter. Most recently, on Monday, November 29th, Edwin M. Kania, Jr. bought 100,000 shares of TransMedics Group stock. The stock was acquired at an average cost of $22.56 per share, with a total value of $2,256,000.00. Learn More on Edwin M. Kania, Jr.'s trading history.
Who are TransMedics Group's active insiders?: TransMedics Group's insider roster includes John Carey (VP), Laura Damme (VP), Stephen Gordon (CFO), Waleed Hassanein (CEO), Edwin Kania, Jr. (Director), Tamer Khayal (Insider), and Miriam Provost (VP). Learn More on TransMedics Group's active insiders.
Are insiders buying or selling shares of TransMedics Group?: In the last year, TransMedics Group insiders bought shares 1 times. They purchased a total of 2,500 shares worth more than $155,000.00. In the last year, insiders at the sold shares 31 times. They sold a total of 231,712 shares worth more than $18,661,937.87. The most recent insider tranaction occured on April, 17th when CEO Waleed H Hassanein sold 4,000 shares worth more than $380,480.00. Insiders at TransMedics Group own 6.7% of the company. Learn More about insider trades at TransMedics Group.
Information on this page was last updated on 4/17/2024.

Edwin M. Kania, Jr. Insider Trading History at TransMedics Group

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/29/2021	Buy	100,000	$22.56	$2,256,000.00
5/6/2019	Buy	33,333	$16.00	$533,328.00

Edwin M. Kania, Jr. Buying and Selling Activity at TransMedics Group

TransMedics Group Company Overview

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Today's Range

Now: $89.25

$86.49

$89.50

50 Day Range

MA: $82.93

$70.86

$95.65

2 Week Range

Now: $89.25

$36.42

$99.63

Volume

444,257 shs

Average Volume

685,106 shs

Market Capitalization

$2.92 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.99

Exposed: 10 CENT Crypto to Explode April 20th?

From True Market Insiders | Ad